OR WAIT null SECS
March 27, 2020
The strategic alliance provides an integrated product offering around drug discovery and development.
The transgenic mouse R&D platform will support the discovery of fully-human monoclonal antibodies.
March 20, 2020
Emergent BioSolutions will help develop and manufacture an oral vaccine candidate and will develop plasma-based antibody therapeutics.
March 19, 2020
Belgian-based bioprocessing provider, Univercells, has launched a CDMO, Exothera, that will support developers of cell and gene therapies through process development and production of viral vectors.
Synairgen, a respiratory drug discovery and development company, has announced that it has received expedited approvals to conduct a trial of its inhaled formulation of interferon-beta-1a, SNG001, in COVID-19 patients.
The acquisition will expand Dover’s biopharma and hygienic applications capabilities by enhancing its portfolio of flow control technologies with flow rate sensors.
The partners have initiated an observational case-control study of siltuximab in patients with COVID-19 who have developed serious respiratory complications.
March 13, 2020
On March 11, 2020, Chancellor Rishi Sunak delivered the 2020 Budget to the government of the United Kingdom, revealing the proposed spending and tax plans for the conservative government for the coming year.
The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Teva Pharmaceutical’s migraine therapy, Ajovy (fremanezumab).
March 11, 2020
Through the agreement, Emergent will manufacture the vaccine, which is formulated based on Novavax’s proprietary recombinant protein nanoparticle technology platform and its Matrix-M adjuvant to boost immune responses.